IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris

References

• Geha RS, Rosen FS. Intravenous immunoglobulin therapy. Therapeutic immunology, KF Austen, SJ Burakoff, FS Rosen, TB Strom. Blackwell Science, Cambridge, MA 1996; 280–296
   Google Scholar
• Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997; 126: 721–730
   PubMed Web of Science ®Google Scholar
• Dickler HB, Gelfand EW. Current perspectives on the use of intravenous immunoglobulin. Adv Intern Med 1996; 41: 641–680
   PubMedGoogle Scholar
• Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: Therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684–685
   PubMed Web of Science ®Google Scholar
• Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: Experience in six patients. Br J Dermatol 1995; 133: 289–293
   PubMed Web of Science ®Google Scholar
• Messer G, Sizmann N, Feucht J, Meurer M. High dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995; 133: 1014–1016
   PubMed Web of Science ®Google Scholar
• Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996; 135: 128–129
   PubMedGoogle Scholar
• Wever S, Zillikens D, Brocker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 862–863
   PubMedGoogle Scholar
• Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering disease: An evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–874
   PubMed Web of Science ®Google Scholar
• Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 1049–1057
   PubMedGoogle Scholar
• Ahmed A. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679–690
   PubMed Web of Science ®Google Scholar
• Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. J Am Acad Dermatol 1998; 134: 80–86
   Google Scholar
• Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358–363
   PubMed Web of Science ®Google Scholar
• Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. JEADV 2006; 20: 548–552
   Google Scholar
• Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 2002; 105: 192–198
   PubMed Web of Science ®Google Scholar
• Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991; 68: 1430–1436
   PubMedGoogle Scholar
• Hilgartner MW, Bussel J. Use of intravenous gammaglobulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 1987; 83: 25–29
   PubMed Web of Science ®Google Scholar
• Dammacco F, Iodice G, Campobasso N. Treatment of adult patients with ITP with IVIg: Effect on circulating T cell subsets and PWM-induced antibody synthesis in vitro. Br J Hematol 1986; 62: 125–135
   PubMed Web of Science ®Google Scholar
• Berchtold P, McMillan R. Intravenous immunoglobulin: New aspects of mechanism of action in chronic ITP. Immunotherapy with intravenous immunoglobulins, P Imbach. Academic Press, San Diego, CA 1991; 245
   Google Scholar
• Berger M, Rosenkranz P, Brown CY. Intravenous and standard immune serum globulin preparations interfere with uptake of 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985; 34: 227–236
   PubMedGoogle Scholar
• Jordan SC, Toyoda M. Treatment of autoimmune disease and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994; 97(Suppl. 1)31–38
   PubMedGoogle Scholar
• Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune disease. N Engl J Med 1999; 340: 227–228
   PubMed Web of Science ®Google Scholar
• Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′5′-monophosphate levels resulting in suppression of tumor necrosis factor alpha and interleukin-1 production. Immunology 1991; 72: 497–501
   PubMed Web of Science ®Google Scholar
• Rosario TL, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22: 35–40
   PubMedGoogle Scholar
• Akman A, Jiao D, Bystryn JC. Limitations of ELISA assays for antibodies against Dsg1 and Dsg3 in patients with pemphigus. Arch Dermatol 2002; 138: 1252–1253
   PubMedGoogle Scholar
• Ahmed AR, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol 2002; 46: 42–49
   PubMed Web of Science ®Google Scholar
• Wetter DA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: A retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80: 41–47
   PubMed Web of Science ®Google Scholar
• Struff WG, Klasser M, Eckert V, Dietrich RL. Safety monitoring of a polyvalent immunoglobulin preparation:documentation of 15,548 administrations. Int J Clin Pharmacol Ther 2005; 43(9)420–428, September
   PubMedGoogle Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglogulin therapy. Int Immunopharmacol 2006; 6: 535–542
   PubMed Web of Science ®Google Scholar
• Sami N, Shol KC, Ahmed RA. Influence of intravenous immunoglogulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003; 13: 377–381
   PubMedGoogle Scholar
• Schultze HE, Heremans JF. Turnover of the plasma proteins. Molecular biology of human proteins, Elsevier Publishing Company, Amsterdam 1966; Vol. 1: 481–487
   Google Scholar
• Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRN receptor. Thromb Haemost 2002; 88: 898–899
   PubMed Web of Science ®Google Scholar
• Li N, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115: 3440–3450
   PubMed Web of Science ®Google Scholar
• Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6: 683–689
   PubMedGoogle Scholar
• Bystryn JC, Schenkein I, Uhr JW. A model for regulation of antibody synthesis by serum antibody. Prog Immunol 1971; 1: 627–636
   Google Scholar
• Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol 1988; 124: 1702–1704
   PubMedGoogle Scholar